Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CVAC 
CureVac NV (CVAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CVAC (4-star) is a STRONG-BUY. BUY since 44 days. Profits (56.48%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $4.31
1 Year Target Price $4.31
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 86.74% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio 5.78 | 1Y Target Price 4.31 |
Price to earnings Ratio 5.78 | 1Y Target Price 4.31 | ||
Volume (30-day avg) 6 | Beta 2.49 | 52 Weeks Range 2.37 - 5.72 | Updated Date 06/30/2025 |
52 Weeks Range 2.37 - 5.72 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.93 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 34.5% | Operating Margin (TTM) -6128.33% |
Management Effectiveness
Return on Assets (TTM) 19.93% | Return on Equity (TTM) 33.04% |
Valuation
Trailing PE 5.78 | Forward PE 5.24 | Enterprise Value 740450064 | Price to Sales(TTM) 2.31 |
Enterprise Value 740450064 | Price to Sales(TTM) 2.31 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA 2.78 | Shares Outstanding 225159008 | Shares Floating 125861832 |
Shares Outstanding 225159008 | Shares Floating 125861832 | ||
Percent Insiders 57.37 | Percent Institutions 4.7 |
Analyst Ratings
Rating 3 | Target Price 4.31 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CureVac NV
Company Overview
History and Background
CureVac NV, founded in 2000, is a German biopharmaceutical company pioneering mRNA-based therapies. It initially focused on cancer immunotherapies and vaccines before expanding into other therapeutic areas. A key milestone was developing a proprietary mRNA technology platform.
Core Business Areas
- mRNA-based Therapeutics: Development of mRNA-based therapies for various diseases, including oncology, infectious diseases, and rare diseases. This includes designing, synthesizing, and formulating mRNA for targeted delivery.
- Vaccines: Developing mRNA-based vaccines against infectious diseases. The company's early efforts focused on COVID-19 vaccine development, though other vaccine candidates are in the pipeline.
Leadership and Structure
The leadership team consists of a CEO and a management board overseeing various functions, including research, development, and commercial operations. The organizational structure is hierarchical, with departments focused on specific therapeutic areas and functions.
Top Products and Market Share
Key Offerings
- COVID-19 Vaccine (CVnCoV): CureVac's first-generation COVID-19 vaccine candidate. It did not achieve sufficient efficacy in clinical trials. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ). Market share is effectively zero due to lack of regulatory approval.
- Second-Generation COVID-19 Vaccine (CV2CoV): A second-generation COVID-19 vaccine candidate developed in collaboration with GSK. This candidate has shown improved immune response in preclinical and clinical testing, but its future is uncertain given existing vaccines. Competitors include Pfizer (PFE), Moderna (MRNA), and Johnson & Johnson (JNJ). Market share is effectively zero due to no commercial launch
- Oncology Programs: CureVac has several oncology programs in preclinical and clinical development, leveraging its mRNA technology to develop cancer immunotherapies. Specific market share data is not available as these products are not yet approved.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development. The mRNA therapeutics and vaccines market is rapidly growing, driven by the success of mRNA-based COVID-19 vaccines. Intense competition exists.
Positioning
CureVac is positioned as a pioneer in mRNA technology. However, it lags behind companies like Pfizer and Moderna in terms of commercial success in the COVID-19 vaccine market. CureVac aims to differentiate itself through its proprietary mRNA technology and its focus on developing innovative therapies and vaccines.
Total Addressable Market (TAM)
The global mRNA therapeutics and vaccines market is projected to reach hundreds of billions of dollars over the next decade. CureVac's ability to capture a significant share of this TAM depends on its success in developing and commercializing its pipeline products.
Upturn SWOT Analysis
Strengths
- Pioneering mRNA technology platform
- Experienced management team
- Partnerships with leading pharmaceutical companies (e.g., GSK)
- Diversified pipeline of mRNA-based therapies and vaccines
Weaknesses
- Late entrant into the COVID-19 vaccine market
- Lower efficacy of first-generation COVID-19 vaccine compared to competitors
- Significant cash burn
- Reliance on partnerships for funding and development
Opportunities
- Growth in the mRNA therapeutics and vaccines market
- Potential for breakthrough therapies in oncology and other disease areas
- Expansion of partnerships with pharmaceutical companies
- Development of next-generation mRNA technologies
Threats
- Intense competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- BNTX
Competitive Landscape
CureVac faces intense competition from established pharmaceutical companies with greater resources and commercial infrastructure. Its success depends on its ability to differentiate itself through its mRNA technology and develop innovative therapies and vaccines.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow due to the lack of commercially approved products.
Future Projections: Future growth depends on the successful development and commercialization of its pipeline products. Analyst estimates vary widely, but generally anticipate revenue growth in the coming years.
Recent Initiatives: Focus on developing next-generation mRNA technologies and expanding partnerships with pharmaceutical companies.
Summary
CureVac is pioneering mRNA technology, but it faces significant challenges. The company's COVID-19 vaccine efforts were unsuccessful, and it is burning cash. Its future depends on successful pipeline development and strategic partnerships. A positive is that they have partnerships in place.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CureVac NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-08-14 | CEO, MD & Member of Management Board Dr. Alexander Zehnder M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 825 | Website https://www.curevac.com |
Full time employees 825 | Website https://www.curevac.com | ||
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.